Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Navan (NAVN) Sued Over IPO Disclosures; Investors Face April 24 Deadline - Hagens Berman (PR Newswire) +++ NAVAN Aktie -4,27%

HOLOGIC Aktie

 >HOLOGIC Aktienkurs 
66 EUR    +0.8%    (TradegateBSX)
Ask: 65.5 EUR / 110 Stück
Bid: 65 EUR / 110 Stück
Tagesumsatz: 1 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
HOLOGIC Aktie über LYNX handeln
>HOLOGIC Performance
1 Woche: +1,1%
1 Monat: +3,9%
3 Monate: +4,3%
6 Monate: +14,8%
1 Jahr: +16,8%
laufendes Jahr: +4,3%
>HOLOGIC Aktie
Name:  HOLOGIC INC. DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US4364401012 / 879100
Symbol/ Ticker:  HO1 (Frankfurt) / HOLX (NASDAQ)
Kürzel:  FRA:HO1, ETR:HO1, HO1:GR, NASDAQ:HOLX
Index:  S&P500
Webseite:  https://www.hologic.com/
Profil:  Hologic Inc. is a medical technology company specializing in women's health through early detection and treatment via diagnostics products, medical imaging systems, and surgical solutions. It operates across four key segments: Diagnostics, which incl..
>Volltext..
Marktkapitalisierung:  14582.97 Mio. EUR
Unternehmenswert:  14714.27 Mio. EUR
Umsatz:  3567.81 Mio. EUR
EBITDA:  1090.9 Mio. EUR
Nettogewinn:  470.27 Mio. EUR
Gewinn je Aktie:  2.1 EUR
Schulden:  2179.13 Mio. EUR
Liquide Mittel:  1874.52 Mio. EUR
Operativer Cashflow:  949.1 Mio. EUR
Bargeldquote:  2.49
Umsatzwachstum:  -9.95%
Gewinnwachstum:  -35.56%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  HOLOGIC
Letzte Datenerhebung:  01.04.26
>HOLOGIC Kennzahlen
Aktien/ Unternehmen:
Aktien: 223.25 Mio. St.
Frei handelbar: 98.45%
Rückkaufquote: 1.19%
Mitarbeiter: 7070
Umsatz/Mitarb.: 0.5 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 2.11%
Bewertung:
KGV: 31.68
KGV lG: 16.87
KUV: 4
KBV: 3.25
PEG-Ratio: -
EV/EBITDA: 13.49
Rentabilität:
Bruttomarge: 55.62%
Gewinnmarge: 13.18%
Operative Marge: 23.66%
Managementeffizenz:
Gesamtkaprendite: 6.07%
Eigenkaprendite: 10.86%
>HOLOGIC Peer Group
Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege, Onkologie/ Krebs- Behandlung
 
31.03.26 - 16:45
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
 
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects....
25.03.26 - 15:01
HOLX vs. ALGN: Which MedTech Stock Is the Better Investment Pick Now? (Zacks)
 
Align Technology's growth surges on record aligner demand and DSO expansion, while Hologic's near-complete buyout leaves little upside for investors....
20.03.26 - 15:45
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know (Zacks)
 
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store....
19.03.26 - 15:45
Hologic′s Women′s Health Index Flags Alarming Gaps in STI Screening (Zacks)
 
HOLX's Global Women's Health Index shows STI testing stagnates at 10%, leaving nearly 2 billion women at risk despite gains in other screenings....
18.03.26 - 15:45
Should You Hold or Sell HOLX Stock as It Nears the End of Public Phase? (Zacks)
 
Hologic nears its $76 buyout price as Diagnostics faces headwinds, tariffs hurt, and the stock trades at a sector premium....
18.03.26 - 15:24
Is Hologic Stock Outperforming the Dow? (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
10.03.26 - 15:00
What Drives Hologic′s GYN Surgical Strength in a Competitive Market? (Zacks)
 
HOLX expands its GYN Surgical reach with MyoSure, NovaSure and Gynesonics boost as the global women's health devices market grows and minimally invasive demand rises....
06.03.26 - 17:30
Hologic′s Diagnostics Strength in Focus: Is More Upside Ahead? (Zacks)
 
HOLX's Diagnostics unit faces COVID-19 test declines, but Panther Fusion expansion, new assays and AI-driven Genius system support long-term growth potential....
26.02.26 - 00:09
ImpediMed Appoints Medical Technology Commercialization Expert Erik Anderson to Board of Directors (PR Newswire)
 
Former Hologic executive brings nearly two decades of success in hospital sales and commercialization expertise to medical technology leader's board CARLSBAD, Calif., Feb. 25, 2026 /PRNewswire/ -- ImpediMed, a leader in the development and commercialization of medical technologies to......
10.02.26 - 16:06
Is Wall Street Bullish or Bearish on Hologic Stock? (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
30.01.26 - 16:00
HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash (Zacks)
 
Hologic slips after a Q1 EPS and revenue miss, as gross margin fell 150 bps with Diagnostics weakness offset by strong GYN Surgical growth....
30.01.26 - 01:00
Hologic (HOLX) Misses Q1 Earnings and Revenue Estimates (Zacks)
 
Hologic (HOLX) delivered earnings and revenue surprises of -4.46% and -2.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
29.01.26 - 23:42
Hologic Inc Reports Retreat In Q1 Bottom Line (AFX)
 
BEDFORD (dpa-AFX) - Hologic Inc (HOLX) reported earnings for first quarter that Drops, from the same period last yearThe company's earnings totaled $179.1 million, or $0.79 per share. This compare......
29.01.26 - 22:06
Hologic Non-GAAP EPS of $1.04 misses by $0.06, revenue of $1.05B misses by $20M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.01.26 - 22:03
Hologic Announces Financial Results for First Quarter of Fiscal 2026 (Business Wire)
 
– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% –MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #earnings--Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04. Highlights The Company has scheduled for February 5, 2026 a special meeting of stockholders to vote on adopting the merger agreement with funds managed by Blackstone and TPG, and related matters. Revenue of $1,047.8 million increased 2.5% for the quarter, or 1.3% on a constant currency basis. Total organic revenue excluding COVID-19 and related revenue, the divested blood screening and SSI businesses, and the acquired Gynesonics business increased 2.9%, or 1.6% in constant currency. GAAP diluted EPS of $0.79 for the quarter decreased (9.2%), mainly due to favorable foreign exchan...
26.01.26 - 16:45
Stay Ahead of the Game With Hologic (HOLX) Q1 Earnings: Wall Street′s Insights on Key Metrics (Zacks)
 
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Hologic (HOLX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025....
22.01.26 - 17:30
Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week′s Release (Zacks)
 
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
21.01.26 - 20:00
Will Hologic (HOLX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
 
Hologic (HOLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....
21.01.26 - 15:15
Will GYN Surgical Power Hologic′s Growth in the Upcoming Q1 Earnings? (Zacks)
 
HOLX's GYN Surgical unit, boosted by MyoSure, Fluent and Gynesonics, drives 10.2% revenue growth and is likely to lift upcoming Q1 results....
19.01.26 - 15:15
HOLX vs. SYK: Which Medical Device Leader Is a Solid Bet Now? (Zacks)
 
Hologic and Stryker gear up for earnings with diagnostic wins, surgical growth and strategic moves shaping the medical device race....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Don′t marry, be happy. - Hera Lind
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!